NCT06103994已完成不适用
A Randomized, Triple-blinded, Placebo-controlled, Parallel Group Study, to Assess the Effect of Multistrain Probiotic on the Immune Response to the Influenza Vaccination
The Archer-Daniels-Midland Company2 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2023年10月27日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 120
- 试验地点
- 2
- 主要终点
- Change in serum strain-specific geometric mean antibody titers (determined by hemagglutination inhibition [HAI] tests)
研究概览
简要总结
A randomized, triple-blinded, placebo-controlled, parallel group study, to assess the effect of multistrain probiotic on the immune response to the Influenza vaccination
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female adults aged 18-65 years
- •According to the clinical judgment of the physician, appropriate to be vaccinated against the influenza virus.
- •Able to attend study visits, comply with study requirements, and provide reliable and complete reports of AE/SAE.
- •Have been informed and have given written consent for the use of their data in accordance with local regulations before study inclusion.
- •If sexually active, commitment to use contraception methods.
- •Negative pregnancy testing (beta human chorionic gonadotropin test in urine) at V1
排除标准
- •Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care.
- •Asymptomatic chronic conditions or findings (e.g., mild hypertension, dyslipidemia) that are not associated with evidence of end-organ damage are not exclusionary provided that they are being appropriately managed and are clinically stable (i.e., unlikely to result in symptomatic illness within the time-course of this trial) in the opinion of the investigator.
- •Acute or chronic illnesses or conditions which may be reasonably predicted to become symptomatic if treatment were withdrawn or interrupted are exclusionary, even if stable.
- •Acute or chronic illnesses reasonably expected to be associated with increased risks in the event of influenza infection (e.g., cardio-pulmonary diseases, diabetes mellitus, renal or hepatic dysfunction, hemoglobinopathies) are exclusionary, even if stable.
- •Participation in research involving a drug, biologic or device within 45 days before planned date of V
- •History of a serious reaction to a prior influenza vaccination (any influenza vaccine, not exclusive to INFLUVAC TETRA).
- •Hypersensitivity or allergy to INFLUVAC TETRA, its active substance, or components e.g. eggs (ovalbumin, chicken proteins), formaldehyde, cetyltrimethylammonium bromide, polysorbate 80, gentamicin, potassium chloride, potassium dihydrogen phosphate, disodium phosphate dihydrate, sodium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, water for injections.
- •Hypersensitivity or allergy to any of the ingredients of the investigational product (IP) or placebo.
- •Individuals with thrombocytopenia, any coagulation disorder or who are pharmacologically anticoagulated.
- •History of Guillain-Barré Syndrome (GBS) within 6 weeks following a previous influenza vaccine.
- •Receipt of ANY non-influenza vaccine (e.g., hepatitis B vaccine, tetanus vaccine) in the 4 weeks preceding the trial vaccination, and ANY influenza vaccine within 6 months preceding the trial vaccination, or already received the 2023-2024 influenza vaccine (any brand).
- •Planned receipt of any vaccine (other than the INFLUVAC TETRA at V2) during the study
- •Any known or suspected immunosuppressive illness, congenital or acquired, based on medical history and/or physical examination.
- •Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the trial vaccine. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose ≥ 10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.
- •Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the trial vaccine or during the trial.
- •Acute disease at the time of enrolment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature >38.0°C).
- •Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of trial results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).
- •Suspicion or recent history (within one year of planned vaccination) of alcohol or other substance abuse.
- •Smoking individuals.
- •Pregnant female, or individual who is planning on becoming pregnant during the course of the study.
- •Breastfeeding females.
- •Consumption of probiotic food supplements or use of antibiotics 1 month prior to study start.
- •Planned significant change in dietary or exercise practices during the course of the study.
- •Planned travel for more than 14 days during the course of the study.
结局指标
主要结局
Change in serum strain-specific geometric mean antibody titers (determined by hemagglutination inhibition [HAI] tests)
时间窗: V2 (3 weeks), V3 (6 weeks)
Change in serum strain-specific geometric mean antibody titers (determined by hemagglutination inhibition \[HAI\] tests) specific for each of the 3 (out of the 4) virus strains included in the INFLUVAC TETRA vaccine, between intervention and placebo from V2 to V3. Higher values mean better immune response.
次要结局
- VAPI (Vaccinees' Perception of Injection) Questionnaire(V3 (6 weeks))
- Change in GSRS (Gastrointestinal Symptom Rating Scale) questionnaire scoring(V1 (Baseline), V2 (3 weeks), V3 (6 weeks))
- Change in seroconversion rate (as measured by HAI tests)(V2 (3 weeks), V3 (6 weeks))
- Change in geometric mean neutralizing antibody (nAb) titers (as measured by microneutralization assays)(V2 (3 weeks), V3 (6 weeks))
- Change in stool microbiome composition(V1 (Baseline), V3 (6 weeks))
- Change in seroprotection rate (as measured by HAI tests)(V2 (3 weeks), V3 (6 weeks))
- Change in seroprotection rate (as measured by nAb titers in a microneutralization assay)(V2 (3 weeks), V3 (6 weeks))
- Change in seroconversion rate (as measured by nAb titers in a microneutralization assay)(V2 (3 weeks), V3 (6 weeks))
- Change in innate immune response(V2 (3 weeks), V3 (6 weeks))
- Change in the adaptive immune response(V2 (3 weeks), V3 (6 weeks))
- Adverse Events(V3 (6 weeks))
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
3 期
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic EsophagitisEosinophilic EsophagitisNCT05583227AstraZeneca368
已完成
3 期
Bioequivalence Study With Clinical Endpoint for Diclofenac Sodium Topical Gel 1%Osteoarthritis, KneeNCT02913521Akorn, Inc.934
已完成
2 期
Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's SubjectsAlzheimer's DiseaseNCT03817684Tetra Discovery Partners255
已完成
3 期
Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.AsthmaNCT01498679GlaxoSmithKline311
终止
3 期
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).Alzheimer's DiseaseNCT02670083Hoffmann-La Roche813